From: Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
Variables | NCS | p | ||
---|---|---|---|---|
0 n (%) | 1 n (%) | 2 n (%) | ||
Sex | 0.585 | |||
 Female | 44 (26.19%) | 51 (29.14%) | 19 (23.17%) | |
 Male | 124 (73.81%) | 124 (70.86%) | 63 (76.83%) | |
Age | <0.001 | |||
 <65years | 106 (63.10%) | 85 (48.57%) | 25 (30.49%) | |
 ≥65years | 62 (36.90%) | 90 (51.43%) | 57 (69.51%) | |
Tumor size | 0.001 | |||
 <5cm | 120 (71.43%) | 97 (55.43%) | 40 (48.78%) | |
 ≥5cm | 48 (28.57%) | 78 (44.57%) | 42 (51.22%) | |
Differentiation | 0.252 | |||
 Moderate/well | 100 (9.52%) | 101 (57.71%) | 40 (48.78%) | |
 Poor | 68 (40.48%) | 74 (42.29%) | 42 (51.22%) | |
Borrmann type | 0.001 | |||
 I–II | 109 (64.88%) | 87 (49.71%) | 34 (41.46%) | |
 III–IV | 59 (35.12%) | 88 (50.29%) | 48 (58.54%) | |
Tumor depth | <0.001 | |||
 T1 | 35 (20.83%) | 10 (5.71%) | 0 (0) | |
 T2 | 30 (17.86%) | 15 (8.57%) | 2 (2.44%) | |
 T3 | 90 (53.57%) | 100 (57.14%) | 40 (48.78%) | |
 T4 | 13 (7.74%) | 50 (28.57%) | 40 (48.78%) | |
Lymph node | <0.001 | |||
 N0 | 70 (41.67%) | 24 (13.71%) | 6 (7.32%) | |
 N1 | 63 (37.50%) | 81 (46.29%) | 37 (45.12%) | |
 N2 | 30 (17.86%) | 48 (27.43%) | 25 (30.49%) | |
 N3 | 5 (2.98%) | 22 (12.57%) | 14 (17.07%) | |
Distant metastasis | <0.001 | |||
 M0 | 166 (98.81%) | 157 (89.71%) | 70 (85.37%) | |
 M1 | 2 (1.19%) | 18 (10.29%) | 12 (14.63%) | |
pTNM stage | <0.001 | |||
 I | 53 (31.55%) | 14 (8.00%) | 1 (1.22%) | |
 II | 75 (44.64%) | 69 (39.43%) | 18 (21.95%) | |
 III | 38 (22.62%) | 74 (42.29%) | 51 (62.20%) | |
 IV | 2 (1.19%) | 18 (10.29%) | 12 (14.63%) | |
CEA | <0.001 | |||
 ≤5ng/ml | 130 (77.38%) | 117 (66.86%) | 29 (35.37%) | |
 >5ng/ml | 38 (22.62%) | 58 (33.14%) | 53 (64.63%) | |
PLR | <0.001 | |||
 ≤127.8 | 112 (66.67%) | 62 (35.43%) | 20 (24.39%) | |
 >127.8 | 56 (33.33%) | 113 (64.57%) | 62 (75.61%) | |
LMR | <0.001 | |||
 ≤4.93 | 52 (30.95%) | 114 (65.14%) | 71 (86.59%) | |
 >4.93 | 116 (69.05%) | 61 (34.86%) | 11 (13.41%) |